{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T01:27:24Z","timestamp":1784683644284,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.schres.2023.10.041","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T22:28:15Z","timestamp":1699396095000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Making sense of norclozapine levels: 3 clinical axioms"],"prefix":"10.1016","author":[{"given":"Jonathan M.","family":"Meyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.schres.2023.10.041_bb0005","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1177\/00048674211062828","article-title":"Does the clozapine\/norclozapine ratio predict cognitive performance in patients with clozapine-resistant schizophrenia?","volume":"56","author":"Arnautovska","year":"2022","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2023.10.041_bb0010","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/JCP.0000000000001050","article-title":"Gemfibrozil may decrease norclozapine elimination: a case report","volume":"39","author":"Barclay","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.schres.2023.10.041_bb0015","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2125.1994.tb04385.x","article-title":"Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test","volume":"38","author":"Bertilsson","year":"1994","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.schres.2023.10.041_bb0020","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0024-3205(02)01680-6","article-title":"In vitro P-glycoprotein affinity for atypical and conventional antipsychotics","volume":"71","author":"Boulton","year":"2002","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.schres.2023.10.041_bb0025","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1124\/jpet.105.092155","article-title":"Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2\/D3 partial agonist","volume":"315","author":"Burstein","year":"2005","journal-title":"J. Pharmacol. Exper. Ther."},{"issue":"8","key":"10.1016\/j.schres.2023.10.041_bb0030","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.2217\/pgs.09.51","article-title":"ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients","volume":"10","author":"Consoli","year":"2009","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.schres.2023.10.041_bb0035","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/14740338.2020.1698545","article-title":"The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy","volume":"19","author":"Costa-Dookhan","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"issue":"10","key":"10.1016\/j.schres.2023.10.041_bb0040","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0169-409X(02)00064-9","article-title":"The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans","volume":"54","author":"Fromm","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.schres.2023.10.041_bb0045","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00210-014-1080-3","article-title":"Different pharmacology of N-desmethylclozapine at human and rat M2 and M 4 mAChRs in neocortex","volume":"388","author":"Gigout","year":"2015","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"issue":"3","key":"10.1016\/j.schres.2023.10.041_bb0050","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes","year":"2017","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2023.10.041_bb0055","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/bcp.14992","article-title":"Body weight gain in clozapine-treated patients: is norclozapine the culprit?","volume":"88","author":"Jessurun","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2023.10.041_bb0060","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.brainres.2011.04.010","article-title":"Behavioral effects of clozapine: involvement of trace amine pathways in C. elegans and M. musculus","volume":"1393","author":"Karmacharya","year":"2011","journal-title":"Brain Res."},{"issue":"6","key":"10.1016\/j.schres.2023.10.041_bb0065","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/00004714-199812000-00013","article-title":"Extrapyramidal symptoms after addition of fluvoxamine to clozapine","volume":"18","author":"Kuo","year":"1998","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2023.10.041_bb0070","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pharmthera.2007.05.004","article-title":"Pharmacology of N-desmethylclozapine","volume":"115","author":"Lameh","year":"2007","journal-title":"Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.schres.2023.10.041_bb0075","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1124\/dmd.112.050278","article-title":"Which metabolites circulate?","volume":"41","author":"Loi","year":"2013","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.schres.2023.10.041_bb0080","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archpsyc.60.1.82","article-title":"Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).[see comment] [erratum appears in Arch Gen Psychiatry.2003 Jul;60(7):735]","volume":"60","author":"Meltzer","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.schres.2023.10.041_bb0085","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.schres.2012.07.029","article-title":"Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2\u00a0mg\/day, but does not enhance efficacy of haloperidol, 2\u00a0mg\/day: comparison with reference dose risperidone, 6\u00a0mg\/day","volume":"141","author":"Meltzer","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.10.041_bb0090","series-title":"The Clozapine Handbook \u2014 Stahl\u2019s Handbooks","author":"Meyer","year":"2019"},{"key":"10.1016\/j.schres.2023.10.041_bb0095","series-title":"The Clinical Use of Antipsychotic Plasma Levels \u2014 Stahl\u2019s Handbooks","author":"Meyer","year":"2021"},{"issue":"4","key":"10.1016\/j.schres.2023.10.041_bb0100","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.psc.2016.07.012","article-title":"Psychopharmacology of persistent violence and aggression","volume":"39","author":"Meyer","year":"2016","journal-title":"Psychiatr. Clin. N. Am."},{"key":"10.1016\/j.schres.2023.10.041_bb0105","first-page":"5606098","article-title":"Ciprofloxacin and clozapine \u2014 a potentially fatal but underappreciated interaction","volume":"2016","author":"Meyer","year":"2016","journal-title":"Case Rep. Psychiatry"},{"key":"10.1016\/j.schres.2023.10.041_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.euroneuro.2019.09.789","article-title":"Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis","author":"Mizuno","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.schres.2023.10.041_bb0115","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1177\/00912700122010717","article-title":"Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations","volume":"41","author":"Olesen","year":"2001","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.schres.2023.10.041_bb0120","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s11126-017-9521-z","article-title":"Clozapine in reducing aggression and violence in forensic populations","volume":"89","author":"Patchan","year":"2018","journal-title":"Psychiatry Q."},{"issue":"2\u20133","key":"10.1016\/j.schres.2023.10.041_bb0125","first-page":"345","article-title":"Acute effects of clozapine-fluvoxamine combination","volume":"79","author":"Peritogiannis","year":"2005","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.schres.2023.10.041_bb0130","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00213-015-4161-1","article-title":"The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review","volume":"233","author":"Polcwiartek","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"10.1016\/j.schres.2023.10.041_bb0135","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/01.jcp.0000106221.36344.4d","article-title":"Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients","volume":"24","author":"Rostami-Hodjegan","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.10.041_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2023.07.002","article-title":"Exploring low clozapine C\/D ratios, inverted clozapine-norclozapine ratios and undetectable concentrations as measures of non-adherence in clozapine patients: a literature review and a case series of 17 patients from 3 studies","author":"Ruan","year":"2023","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.10.041_bb0145","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.schres.2022.03.014","article-title":"Relationship between plasma clozapine\/N-desmethylclozapine and changes in basal forebrain-dorsolateral prefrontal cortex coupling in treatment-resistant schizophrenia","volume":"243","author":"Sarpal","year":"2022","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2023.10.041_bb0150","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.pbb.2012.04.002","article-title":"In vitro P-glycoprotein efflux inhibition by atypical antipsychotics is in vivo nicely reflected by pharmacodynamic but less by pharmacokinetic changes","volume":"102","author":"Schmitt","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"7","key":"10.1016\/j.schres.2023.10.041_bb0155","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/17512433.2019.1617695","article-title":"A comprehensive review of the clinical utility of and a combined analysis of the clozapine\/norclozapine ratio in therapeutic drug monitoring for adult patients","volume":"12","author":"Schoretsanitis","year":"2019","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.schres.2023.10.041_bb0160","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19cs13169","volume":"81","author":"Schoretsanitis","year":"2020","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2023.10.041_bb0165","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/17425255.2016.1154043","article-title":"Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics","volume":"12","author":"Spina","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"Suppl. 1","key":"10.1016\/j.schres.2023.10.041_bb0170","first-page":"S116","article-title":"ACP104 initial phase II results: putative antipsychotic drug and cognition enhancer (Abstracts from the ACNP 45th Annual Meeting. December 3\u20137, 2006. Hollywood, Florida, USA)","volume":"31","author":"Tamminga","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.schres.2023.10.041_bb0175","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00213-020-05746-y","article-title":"A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions","volume":"238","author":"Tan","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"issue":"8","key":"10.1016\/j.schres.2023.10.041_bb0180","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.neuropharm.2010.02.017","article-title":"N-desmethylclozapine (NDMC) is an antagonist at the human native muscarinic M(1) receptor","volume":"58","author":"Thomas","year":"2010","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.schres.2023.10.041_bb0185","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s40262-023-01247-1","article-title":"Association between clozapine plasma concentrations and treatment response: a systematic review, meta-analysis and individual participant data meta-analysis","volume":"62","author":"Tralongo","year":"2023","journal-title":"Clin. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.schres.2023.10.041_bb0190","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/schbul\/sbad030","article-title":"Clozapine optimization: a Delphi consensus guideline from the treatment response and resistance in psychosis working group","volume":"49","author":"Wagner","year":"2023","journal-title":"Schizophr. Bull."},{"issue":"1\u20132","key":"10.1016\/j.schres.2023.10.041_bb0195","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00213-004-1940-5","article-title":"The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine","volume":"177","author":"Weiner","year":"2004","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.schres.2023.10.041_bb0200","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.schres.2004.01.013","article-title":"Effects of typical and atypical antipsychotics on human glycine transporters","volume":"71","author":"Williams","year":"2004","journal-title":"Schizophr. Res."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996423004036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996423004036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T16:04:52Z","timestamp":1699977892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996423004036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":40,"alternative-id":["S0920996423004036"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2023.10.041","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Making sense of norclozapine levels: 3 clinical axioms","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2023.10.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}